Regenerative Medicine Startup Funding
In our updated market reports, you will find everything you need
SUMMARY
This report analyzes publicly disclosed equity rounds raised by pure-play regenerative medicine companies between August 2025 and July 2026, a 12-month window covering every geography. We only kept disclosed equity or equity-like rounds of $300K or more, and excluded companies that were not focused on repairing, replacing, or regenerating damaged cells, tissues, or organs.
Over this period, fundraising in the regenerative medicine market was active but highly selective. The dataset includes 20 disclosed deals and $1.80B raised across 20 unique companies.
Capital in the regenerative medicine market is concentrated at the top. The largest deal accounts for 17.45% of total capital, the top 3 reach 45.68%, and the top 10 reach 87.06%.
Megarounds define the visible market. Half of all disclosed deals are above $50M, and 7 deals are above $100M, which is high for a market with many Series A companies.
The median round size is $60.0M, while the average round size is $89.79M. That gap shows that large financings pull the market total upward.
Fundraising cadence was lumpy. The market averaged 1.67 deals per month, but March 2026 and September 2025 had no qualifying deals, while June 2026 had five.
Gene Therapies lead the regenerative medicine market by both dollars and deal count. The category raised $747.4M across 7 deals, equal to 41.62% of capital and 35.00% of deal activity.
Cell Therapies are the second-largest category by capital. They raised $442.0M across 4 deals, driven by Orca Bio, CREATE Medicines, Vivacta Bio, and Waypoint Bio.
North America dominates the regenerative medicine market. It captured 16 of 20 deals and $1.56B, equal to 87.08% of all disclosed capital.
The stage mix shows a two-speed market. Series A rounds are the most common, but late-stage and large follow-on rounds still hold 58.21% of capital.
Repeat investors are mostly specialist life-science funds, strategic pharma investors, and corporate venture groups. ARCH Venture Partners appears in three deals, while GV, OrbiMed, Loyal Valley Capital, DC Global Ventures, Lilly, Illumina Ventures, DCVC Bio, and Alexandria Venture Investments each appear more than once.
What are all the funding deals in the regenerative medicine market from August 2025 to July 2026?
The table below lists every disclosed equity round raised by pure-play regenerative medicine companies between August 2025 and July 2026. We count as “pure-play” regenerative medicine companies those whose core activity is dedicated to therapies or products that repair, replace, or regenerate damaged cells, tissues, or organs.
Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors when disclosed in the dataset, and the announcement source.
| Company | What they do | Category | Date | Stage | Deal size | Region | Main investors | Source |
|---|---|---|---|---|---|---|---|---|
| Kriya Therapeutics | Single-dose gene therapies for chronic diseases including geographic atrophy, trigeminal neuralgia, focal epilepsy, type 1 diabetes, and MASH | Gene Therapies | Aug 2025 | Unknown | $313.3M | North America | Not specified in dataset | BioSpace |
| Trogenix | Gene therapy constructs for glioblastoma, preparing U.S. and U.K. clinical trials | Gene Therapies | Oct 2025 | Series A | $94.1M | Europe | Not specified in dataset | Trogenix |
| Affinia Therapeutics | Engineered AAV gene therapies for cardiovascular and neurological diseases, including BAG3 dilated cardiomyopathy | Gene Therapies | Oct 2025 | Series C | $40M | North America | GV; Lilly; Alexandria Venture Investments | Affinia Therapeutics |
| Pelage Pharmaceuticals | Regenerative treatments for hair loss by reactivating dormant hair follicle stem cells | Stem Cell Therapies | Oct 2025 | Series B | $120M | North America | ARCH Venture Partners; GV | Pelage Pharmaceuticals |
| Aspen Neuroscience | Autologous iPSC-derived neuronal replacement therapies for Parkinson’s disease and other neurodegenerative conditions | Stem Cell Therapies | Nov 2025 | Series C | $115M | North America | ARCH Venture Partners; OrbiMed | Aspen Neuroscience |
| Orca Bio | High-precision allogeneic cell therapies, including Orca-T for transplant-related immune reconstitution | Cell Therapies | Jan 2026 | Series D+ | $250M | North America | Not specified in dataset | Orca Bio |
| STRM.BIO | Non-viral, cell-derived delivery technologies for in vivo cell engineering and gene therapy | Gene Therapies | Jan 2026 | Seed | $8M | North America | Not specified in dataset | PR Newswire |
| Juvena Therapeutics | AI-enabled regenerative biologics designed to restore tissue function in neuromuscular and age-related diseases | Regenerative Biologics | Jan 2026 | Series B | $33.5M | North America | Lilly | Business Wire |
| Cellares | Automated integrated development and manufacturing services for cell therapies through Smart Factories and Cell Shuttle systems | Regenerative Manufacturing Services | Jan 2026 | Series D+ | $257M | North America | DC Global Ventures | Cellares |
| Pandorum Technologies | Programmable regenerative medicine and tunable exosome-based therapies for ocular surface and degenerative diseases | Exosome Therapies | Feb 2026 | Series B | $18M | Asia-Pacific | Not specified in dataset | Business Wire |
| Omeza Holdings | FDA-cleared regenerative wound care products using marine-derived biologic compounds | Wound Regeneration Products | Apr 2026 | Series A | $8.5M | North America | Not specified in dataset | Omeza |
| Vivacta Bio | In vivo CAR-T cell therapies for cancer and autoimmune diseases | Cell Therapies | Apr 2026 | Series A | $50M | Asia-Pacific | OrbiMed; Loyal Valley Capital; DC Global Ventures | PR Newswire |
| Latus Bio | Engineered AAV gene therapies for Huntington’s disease, CLN2 disease, and broader CNS indications | Gene Therapies | May 2026 | Series A | $97M | North America | DCVC Bio | PackGene |
| CREATE Medicines | In vivo immune programming therapies using mRNA-LNP technology to engineer immune cells inside the body | Cell Therapies | May 2026 | Series B | $122M | North America | ARCH Venture Partners; Alexandria Venture Investments | CREATE Medicines |
| YolTech Therapeutics | In vivo gene-editing medicines using editor and LNP delivery platforms for genetic, metabolic, cardiovascular, and autoimmune diseases | Gene Therapies | May 2026 | Series C | $70M | Asia-Pacific | Loyal Valley Capital | YolTech Therapeutics |
| Waypoint Bio | AI-designed in vivo CAR-T therapies for solid tumors using spatial biology and proprietary lentiviral vectors | Cell Therapies | Jun 2026 | Series A | $20M | North America | Not specified in dataset | BioSpace |
| Fesarius Therapeutics | DermiSphere, an FDA-cleared hydrogel dermal regeneration template for wound management | Tissue Engineering | Jun 2026 | Series A | $20M | North America | Not specified in dataset | Citybiz |
| SonoThera | Ultrasound-mediated nonviral genetic medicines for diseases including Duchenne muscular dystrophy | Gene Therapies | Jun 2026 | Series B | $125M | North America | Illumina Ventures | SonoThera |
| Syntax Bio | Programmed stem-cell-derived therapies using Cellgorithm technology, including pancreatic beta cell therapy for type 1 diabetes | Stem Cell Therapies | Jun 2026 | Series A | $14.4M | North America | Illumina Ventures; DCVC Bio | BioSpace |
| Rapalogix Health | Cellular longevity and skin-health therapeutics designed to restore youthful cellular function in skin | Regenerative Biologics | Jun 2026 | Series A | $20M | North America | Not specified in dataset | Business Wire |
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this regenerative medicine funding tracker by reviewing publicly disclosed equity rounds raised by pure-play regenerative medicine companies between August 2025 and July 2026. A company counts as pure-play when more than 80% of its activity is dedicated to therapies or products that repair, replace, or regenerate damaged cells, tissues, or organs.
We applied four filters to build the dataset. First, we only included equity rounds, so grants, debt-only facilities, acquisitions, licensing deals, and non-equity financing are excluded. Second, we only counted rounds of $300K or more. Third, we only kept pure-play regenerative medicine companies. And fourth, every entry had to be confirmed by a direct company announcement, a press release, or a tier-1 or strong sector media report, with the source URL preserved for every row.
The final dataset contains 20 disclosed deals across 20 unique companies, and every average, median, share, and concentration ratio is computed on that disclosed sample. Vivacta Bio was reported as over $50M, so we used $50M as the conservative disclosed lower bound. Orca Bio disclosed $250M in aggregate equity from its two most recent financing rounds, and we included that aggregate amount because the announcement did not separate the exact Series F component.
How active has fundraising been in the regenerative medicine market?
As of July 2026, fundraising in the regenerative medicine market has been active but uneven over the past 12 months. The dataset includes 20 disclosed equity rounds and $1.80B raised across 20 unique companies.
The market averaged 1.67 deals per month, but the activity was not steady. September 2025 and March 2026 had no qualifying deals, while June 2026 had five disclosed rounds.
Capital flow was also lumpy. January 2026 was the strongest month by dollars at $298.5M, helped by Cellares, Orca Bio, Juvena Therapeutics, and STRM.BIO appearing around that period.
June 2026 had the highest deal count but not the highest dollar total. That matters because the month showed more breadth, while January showed how one infrastructure megadeal can make a period look unusually strong.
How concentrated has fundraising been in the regenerative medicine market?
As of July 2026, fundraising in the regenerative medicine market has been highly concentrated over the past 12 months. The top 1 deal represents 17.45% of capital, the top 3 reach 45.68%, and the top 10 reach 87.06%.
This means the headline market total should not be read as evenly distributed funding strength. A small group of companies explains most of the $1.80B total.
The concentration is visible by category as well. Gene Therapies and Cell Therapies together account for 66.23% of capital and 55.00% of disclosed deals.
The median company is therefore much less capitalized than the total suggests. The median round size is $60.0M, far below the largest financings in the dataset.
How much of the regenerative medicine funding signal is driven by outliers?
As of July 2026, a meaningful share of the regenerative medicine funding signal is driven by outliers over the past 12 months. The average round size is $89.79M, while the median is $60.0M, showing that large rounds pull the average upward.
The largest deal, Kriya Therapeutics at $313.3M, alone accounts for 17.45% of disclosed capital. Cellares and Orca Bio also each raised more than $250M.
Megarounds are common rather than exceptional in this dataset. Ten disclosed rounds are above $50M, equal to half of all deals, and 7 rounds are above $100M.
Excluding rounds above $50M leaves only $232.4M of capital. That means the visible regenerative medicine market is mostly shaped by large clinical, platform, and manufacturing financings.
Is the regenerative medicine market broad with many targets, or narrow with few fundable companies?
As of July 2026, the regenerative medicine market looks narrow rather than broad over the past 12 months. The dataset contains 20 disclosed deals across 20 unique companies, with no company appearing twice in the row-level sample.
The narrowness is not because only one modality attracted funding. Gene Therapies, Cell Therapies, Stem Cell Therapies, Regenerative Biologics, Tissue Engineering, Exosome Therapies, Wound Regeneration Products, and Manufacturing Services all appear.
The issue is that fundability is concentrated in companies with specific therapeutic platforms, delivery systems, clinical paths, or manufacturing leverage. Broad regenerative claims without precise mechanisms are not what attracts the largest checks.
The market therefore has multiple technical lanes but a limited number of companies that can raise at scale. Investors appear to be selective rather than broadly funding every regenerative medicine angle.
Is regenerative medicine mostly an early-stage formation market or a late-stage scaling market?
As of July 2026, the regenerative medicine market is split between early-stage formation and late-stage scaling over the past 12 months. Early-stage rounds hold $750.5M, or 41.79% of capital, while late-stage and large follow-on financings hold $1.05B, or 58.21%.
Series A is the most common stage, with 8 of 20 deals. But those rounds account for only 18.04% of disclosed capital, which shows that company formation is active but not where most dollars sit.
Series D+ rounds are only 2 deals, yet they account for 28.23% of capital. That reflects the cost of commercial readiness, manufacturing scale, and late-stage execution in regenerative medicine.
The market has a visible funding cliff. Small Series A rounds around $8.5M to $20M coexist with platform-validation and scale-up rounds above $100M.
Which categories attract the most investor attention in regenerative medicine?
As of July 2026, Gene Therapies attract the most investor attention in the regenerative medicine market over the past 12 months. The category raised $747.4M across 7 deals, equal to 41.62% of capital and 35.00% of deal count.
Cell Therapies rank second by capital, with $442.0M raised across 4 deals. Together, Gene Therapies and Cell Therapies account for nearly two-thirds of the total dollars in the dataset.
Stem Cell Therapies also matter, with $249.4M across 3 deals. But Pelage Pharmaceuticals and Aspen Neuroscience account for nearly all of that category’s capital.
The investor attention pattern is clear. Programmable therapeutic modalities receive the largest commitments, while wound, dermal, exosome, and biologic categories remain smaller in dollar terms.
Which categories attract disproportionately large checks in the regenerative medicine market?
As of July 2026, Regenerative Manufacturing Services attracts the most disproportionately large check in the regenerative medicine market over the past 12 months. It represents only 5.00% of deals but 14.31% of capital, giving it the highest capital share to deal share ratio at 2.86.
Cellares is the entire category in this dataset, with a $257M Series D+ round. That shows that manufacturing bottlenecks can command therapeutic-platform-level capital even without owning a therapeutic asset.
Cell Therapies also attract large checks relative to deal count. They represent 20.00% of deals and 24.61% of capital, with an average round size of $110.5M.
Gene Therapies are large and broad at the same time. The category’s average round size is $106.8M, and its median is $94.1M, which suggests the signal is not dependent on only one company.
Which geographies matter most for fundraising in the regenerative medicine market?
As of July 2026, North America matters most for fundraising in the regenerative medicine market over the past 12 months. The region captures 16 of 20 deals and $1.56B, equal to 87.08% of disclosed capital.
North America is not only more active by deal count. Its capital share is higher than its deal share, which means North American rounds are also larger on average.
Asia-Pacific produced 3 deals and $138.0M, equal to 15.00% of deals and 7.68% of capital. The region is present, but its disclosed rounds are generally smaller than North American rounds.
Europe appears through one deal, Trogenix at $94.1M. The European issue in this dataset is not small round size, but low disclosed deal frequency.
Is the regenerative medicine opportunity set broad or concentrated in one hub?
As of July 2026, the regenerative medicine opportunity set is highly concentrated in North America over the past 12 months. North America holds 80.00% of deals and 87.08% of disclosed capital.
Asia-Pacific and Europe are visible, but neither matches North America’s depth. Asia-Pacific produced 3 deals, while Europe produced only one qualifying disclosed round.
Latin America, the Middle East, and Africa had no qualifying disclosed equity rounds in the dataset. That absence is decision-relevant, not just statistical noise.
The footprint suggests that private pure-play regenerative medicine company building remains concentrated in North America, Europe, China, and India during this period. Other regions may have scientific activity, but they did not show up in the disclosed venture sample.
Is regenerative medicine a market of small experiments or scaled financings?
As of July 2026, regenerative medicine is a market of scaled financings more than small experiments over the past 12 months. Half of all disclosed deals are above $50M, and 7 of 20 are above $100M.
The lower end of the market is thin. There are no deals below $5M, 4 deals between $5M and $20M, and 5 deals between $20M and $50M.
The practical lower bound for serious institutional Series A regenerative medicine rounds in this dataset is around $20M. Smaller rounds, such as STRM.BIO, Omeza, and Syntax Bio, read more like platform validation, bridge, or continuation capital.
The size pattern reflects the biology. Regenerative medicine companies often need enough capital to reach IND submissions, clinical trials, Phase 3 preparation, commercialization, or manufacturing scale.
Who are the investors that appear the most in regenerative medicine fundraising?
As of July 2026, repeat investors in the regenerative medicine market are mostly specialist life-science investors and strategic pharma-linked capital. ARCH Venture Partners appears in three qualifying deals, while several investors appear in two.
ARCH Venture Partners appears across Pelage Pharmaceuticals, Aspen Neuroscience, and CREATE Medicines. That spread suggests a broader regenerative medicine thesis rather than a narrow bet on one modality.
GV appears in Pelage Pharmaceuticals and Affinia Therapeutics, while OrbiMed appears in Aspen Neuroscience and Vivacta Bio. Loyal Valley Capital, DC Global Ventures, Lilly, Illumina Ventures, DCVC Bio, and Alexandria Venture Investments also appear more than once.
The repeat-investor list matters because regenerative medicine requires technical underwriting. Specialist and strategic investors can evaluate development risk, manufacturing complexity, clinical milestones, and downstream partnering paths better than generalist momentum capital.
INSIGHTS
The insights below come from reviewing every disclosed equity round in the regenerative medicine market between August 2025 and July 2026. They are not row-by-row summaries. They are the reusable patterns that kept showing up across the 20-deal dataset, and they are meant to stay useful when reading any future regenerative medicine funding announcement.
Gene and cell therapies define the center of gravity. Gene Therapies and Cell Therapies together account for 66.23% of capital and 55.00% of deals. That suggests investors still view programmable therapeutic modalities as the highest-conviction part of regenerative medicine.
Manufacturing is a bottleneck investors are willing to fund like a therapeutic platform. Cellares is only one deal, but it absorbs 14.31% of all capital. In regenerative medicine, infrastructure that solves production constraints can be as valuable as asset ownership.
The market is much more top-heavy than the total implies. The top 3 deals account for 45.68% of capital, and the top 10 account for 87.06%. Aggregate funding should therefore be read as a small-winners story.
The average round size overstates the typical company. The average round is $89.79M, while the median is $60.0M. That gap shows that a handful of large rounds drives the capital intensity narrative.
Megarounds are not rare in this dataset. Half of all deals are above $50M, and 35.00% are above $100M. Investors appear willing to fund regenerative medicine only when large clinical, manufacturing, or regulatory milestones justify the check.
Series A activity shows formation, but not broad capital depth. Series A rounds represent 40.00% of deals but only 18.04% of capital. The market is forming new companies, but the largest dollars still wait for stronger evidence.
Late-stage execution is disproportionately expensive. Series D+ rounds account for only 10.00% of deals but 28.23% of capital. Commercial readiness and manufacturing scale are unusually costly in regenerative medicine.
The market has a two-speed structure. Small Series A rounds around $8.5M to $20M coexist with validation rounds above $100M. The gap suggests a funding cliff between platform formation and clinical execution.
North America dominates by both activity and check size. The region holds 80.00% of deals and 87.08% of capital. Its higher capital share shows that North America is not just more active, but also better capitalized.
Asia-Pacific is present but not yet equally capitalized. The region produced 15.00% of deals but only 7.68% of capital. Its disclosed private rounds were generally smaller than North American rounds during this period.
Europe’s issue is frequency, not deal quality. Trogenix raised $94.1M, close to the North American median. The problem is that Europe produced only one qualifying disclosed deal.
Gene therapy’s lead is broad rather than single-company dependent. Kriya, SonoThera, Latus Bio, Trogenix, YolTech, Affinia, and STRM.BIO span different technologies and indications. That breadth makes the category’s lead more durable.
Delivery innovation is one of the strongest funding signals. The largest gene therapy rounds cluster around engineered AAV, ultrasound-mediated nonviral delivery, in vivo editing, and cell-derived delivery. Investors appear to underwrite delivery improvements as much as disease biology.
Cell therapy is moving beyond classic ex vivo oncology CAR-T. Orca Bio and CREATE Medicines show interest in commercial readiness and in vivo immune programming. Scalable or differentiated therapeutic formats are becoming central to the category.
Stem Cell Therapies depend on late translational evidence. Pelage Pharmaceuticals and Aspen Neuroscience account for most of the category’s capital. The category’s strength is therefore more about advanced programs than broad early formation.
Commercial regenerative products raised smaller rounds than therapeutic platforms. Wound and dermal regeneration products appear in the dataset, but with modest round sizes. Venture capital seems to value durable disease modification and platform scalability more than cleared products alone.
Exosome therapies remain real but cautious. Pandorum’s $18M Series B shows the category can attract capital. The modest size suggests investors still need stronger clinical translation before funding exosome platforms at gene-therapy-like levels.
Follow-on funding dominates the market signal. Only three first financings appear in the dataset: Trogenix, Waypoint Bio, and Rapalogix Health. Investors are prioritizing existing platforms with accumulated evidence over broad new-company creation.
Specialist capital matters because the underwriting is technical. The repeat investor list is dominated by life-science specialists, pharma strategics, and corporate venture groups. That is a credibility signal in a market where development, manufacturing, and regulatory paths are difficult to assess.
Specific milestone language should be weighted heavily. The clearest use-of-proceeds statements point to IND submissions, clinical entry, Phase 3 preparation, commercial launch, or manufacturing scale. Future rounds without milestone specificity should be discounted against similarly sized rounds with defined gates.
Regenerative medicine is becoming more programmable than product-led. The strongest financings center on gene delivery, in vivo engineering, iPSC differentiation, and manufacturing automation. The market is moving beyond tissue repair products toward scalable therapeutic systems.
Credibility depends on precision. Companies with a specific modality, target tissue, delivery method, and next milestone raised larger rounds. Broad “regeneration” claims are much weaker than precise mechanisms tied to near-term proof points.
BioSpace (Kriya Therapeutics), Trogenix (Series A), Affinia Therapeutics (Series C), Pelage Pharmaceuticals (Series B), Aspen Neuroscience (Series C), Orca Bio (aggregate financing), PR Newswire (STRM.BIO), Business Wire (Juvena Therapeutics), Cellares (Series D), Business Wire (Pandorum Technologies), Omeza (Series A), PR Newswire (Vivacta Bio), PackGene (Latus Bio), CREATE Medicines (Series B), YolTech Therapeutics (Series C), BioSpace (Waypoint Bio), Citybiz (Fesarius Therapeutics), SonoThera (Series B), BioSpace (Syntax Bio), Business Wire (Rapalogix Health)
Related blog posts
- An overview of funding deals in the regenerative medicine market
- Who has raised the most money in the regenerative medicine market?
- Who are the most valuable companies in the regenerative medicine market?
